Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Identifying the drivers of genetic risk in patients with multiple primary melanoma.

The Journal of investigative dermatology·2026

Same author

Identification of MITF-regulated transcript isoforms of ubiquitously expressed genes.

The Journal of investigative dermatology·2026

Same author

UV induces common cutaneous amyloid-like melanosomal protein aggregates.

bioRxiv : the preprint server for biology·2025

Same author

Melanin-Driven Delayed CPD Formation Is Independent of Melanin Biosynthesis Pathway.

The Journal of investigative dermatology·2025

Same author

Lysosomal reduced thiols are essential for mouse embryonic development.

Proceedings of the National Academy of Sciences of the United States of America·2025

Same author

Type 2 immunity links eczematous and lichenoid eruptions caused by immune checkpoint inhibitors.

Journal of the American Academy of Dermatology·2025

Same journal

Tools for computational analysis of moving boundary problems in cellular mechanobiology.

Wiley interdisciplinary reviews. Systems biology and medicine·2020

Same journal

Cellular reprogramming: Mathematics meets medicine.

Wiley interdisciplinary reviews. Systems biology and medicine·2020

Same journal

Thermoregulation: A journey from physiology to computational models and the intensive care unit.

Wiley interdisciplinary reviews. Systems biology and medicine·2020

Same journal

Mammalian cell and tissue imaging using Raman and coherent Raman microscopy.

Wiley interdisciplinary reviews. Systems biology and medicine·2020

Same journal

Regulating cellular cyclic adenosine monophosphate: "Sources," "sinks," and now, "tunable valves".

Wiley interdisciplinary reviews. Systems biology and medicine·2020

Same journal

Molecular networks in Network Medicine: Development and applications.

Wiley interdisciplinary reviews. Systems biology and medicine·2020

See all related articles

Search research articles

Related Experiment Video

Updated: May 14, 2026

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Developing melanoma therapeutics: overview and update.

John B Korman¹, David E Fisher

¹Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Wiley Interdisciplinary Reviews. Systems Biology and Medicine

|February 15, 2013

Summary

This summary is machine-generated.

Targeting melanoma with BRAF inhibitors and immune checkpoint blockers shows promise but faces challenges. Combining therapies may improve patient response and durability, requiring further research for optimal strategies.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models

Published on: September 6, 2024

Related Experiment Videos

Last Updated: May 14, 2026

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models

Published on: September 6, 2024

Area of Science:

Oncology
Immunology
Pharmacology

Background:

Melanoma is a deadly cancer with limited advanced treatment options.
Recent advancements include BRAF inhibitors (e.g., Vemurafenib) and immune checkpoint inhibitors (e.g., ipilimumab).
Challenges include incomplete responses and rapid development of therapeutic resistance.

Purpose of the Study:

To review current therapeutic strategies for advanced melanoma.
To explore the potential of combination therapies.
To identify future research directions for optimizing melanoma treatment.

Main Methods:

Review of preclinical and clinical studies on melanoma therapies.
Analysis of targeted therapies, including BRAF inhibitors and CTLA-4 blockade.
Discussion of resistance mechanisms and combination strategies.

Main Results:

Selective BRAF inhibitors (SBIs) and immune checkpoint inhibitors have shown clinical efficacy.
Therapeutic resistance remains a significant obstacle, leading to relapse and mortality.
Combination therapies, particularly involving SBIs and resistance pathway inhibitors, show promise.

Conclusions:

Combined therapeutic modalities may enhance response rates and durability in melanoma.
Further preclinical and clinical studies are essential to determine optimal combination therapies.
Identifying responsive melanoma subtypes and optimizing dosing/timing are critical for future treatment strategies.